A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Aims: To assess the effects of renal impairment (RI) on the efficacy and safety of ipragliflozin in patients with type 2 diabetes mellitus (T2DM). Methods: A cohort of Japanese patients with T2DM and mild to moderate RI and poor glycaemic control, despite diet/exercise therapy alone or diet/exercise therapy in combination with an oral hypoglycaemic agent (an α‐glucosidase inhibitor, a sulfonylurea, or pioglitazone), were randomized in a double‐blind manner to 50 mg ipragliflozin or placebo once daily for 24 weeks. The patients continued open‐label ipragliflozin for a 28‐week extension period (total treatment duration: 52 weeks). Results: Ipragliflozin significantly decreased glycated haemoglobin (HbA1c) and fasting plasma glucose ( FPG ) levels and body weight from baseline to week 24 (last observation carried forward) compared with placebo in all patients with RI . The decreases in HbA1c and FPG levels were statistically significant in patients with mild RI , but not in patients with moderate RI . Ipragliflozin significantly reduced body weight in both RI groups. The improvements in glycaemic control were maintained in the 28‐week extension period. Ipragliflozin was associated with no clinically significant safety concerns, and its safety profiles were not influenced by the severity of RI . Conclusions: Ipragliflozin significantly improved glycaemic control and body weight in patients with T2DM with mild RI , but did not improve glycaemic control in patients with moderate RI . Ipragliflozin is a valid treatment option for patients with mild RI but not those with moderate RI .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
Research works printed but not linked: 19
- 10.1152/ajprenal.2001.280.1.F10 · DOI · Paper page
- 10.1038/ki.2009.87 · DOI · Paper page
- Krook A, 1997, Improved glucose tolerance restores insulin‐stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto‐Kakizaki rats, Diabetes, 46, 2110, 10.2337/diab.46.12.2110 · DOI · Paper page
- 10.1254/jphs.12089FP · DOI
- 10.1007/s00210-011-0713-z · DOI
- 10.1111/jdi.12156 · DOI · Paper page
- 10.1016/j.jdiacomp.2012.11.005 · DOI
- 10.1111/dom.12038 · DOI · Paper page
- 10.1007/s13340-012-0069-8 · DOI · Paper page
- 10.1053/j.ajkd.2008.12.034 · DOI · Paper page
- 10.1007/s13340‐014‐0184‐9 · DOI
- 10.1111/dom.12331 · DOI · Paper page
- 10.1007/s13340-014-0182-y · DOI
- 10.1111/dom.12090 · DOI · Paper page
- 10.2337/dc12-1503 · DOI · Paper page
- 10.1007/s13340-014-0164-0 · DOI
- 10.1016/j.diabres.2014.07.020 · DOI
- 10.1111/j.1463-1326.2012.01630.x · DOI · Paper page
- 10.2337/dc11-1926 · DOI · Paper page
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Metadata
- Authors
- Kashiwagi, A., Takahashi, H., Ishikawa, H., Yoshida, S., Kazuta, K., Utsuno, A., & Ueyama, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-01-21
- Volume
- 17
- Issue
- 2
- Pages
- 152-160
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1557519555
- Cited by
- 116
- References
- 3
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study. https://app.cochat.ai/papers/10.1111/dom.12403
- The paper
- Kashiwagi, A., Takahashi, H., Ishikawa, H., Yoshida, S., Kazuta, K., Utsuno, A., & Ueyama, E. (2015). A randomized, double‐blind, placebo‐controlled study on long‐term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long‐Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12403
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.